Last reviewed · How we verify
Fluvastatin, Tacrolimus, Mycophenolat Mofetil
Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients.
Fluvastatin, Tacrolimus, and Mycophenolate Mofetil are immunosuppressive and lipid-lowering drugs primarily used in transplant patients and for managing hypercholesterolemia. Fluvastatin is a statin that reduces cholesterol by inhibiting HMG-CoA reductase. Tacrolimus is an immunosuppressant that prevents organ rejection by inhibiting T-cell activation. Mycophenolate Mofetil is another immunosuppressant that works by inhibiting purine synthesis in lymphocytes. These drugs are prescribed in combination therapy to manage the complex needs of transplant patients and those with autoimmune conditions. Each drug has distinct mechanisms and side effect profiles, requiring careful monitoring and management.
At a glance
| Generic name | Fluvastatin, Tacrolimus, Mycophenolat Mofetil |
|---|---|
| Sponsor | University Hospital Schleswig-Holstein |
| Drug class | ["Statins", "Immunosuppressants", "Immunosuppressants"] |
| Target | ["HMG-CoA reductase", "T-cell activation", "IMP dehydrogenase"] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Fluvastatin lowers cholesterol by inhibiting HMG-CoA reductase, while Tacrolimus and Mycophenolate Mofetil suppress the immune system to prevent organ rejection.
Approved indications
Boxed warnings
- Increased risk of infection and malignancy (Tacrolimus, Mycophenolate Mofetil)
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Increased liver enzymes
- Tremor
- Anemia
- Leukopenia
Drug interactions
- Cyclosporine
- Aspirin
- Antacids
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
| 2023 | ||
| 2022 | ||
| 2024 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: